{
  "document": "Foundation_28",
  "Genomic Findings": [
    {
      "Name": "ERBB2 amplification",
      "Clinical": [
        "Ado-trastuzumab emtansine",
        "Trastuzumab",
        "Trastuzumab + Pertuzumab",
        "Trastuzumab + Tucatinib",
        "Fam-trastuzumab deruxtecan",
        "Lapatinib",
        "Lapatinib + Letrozole",
        "Neratinib",
        "Margetuximab"
      ],
      "No Clinical": ["Afatinib", "Dacomitinib"]
    },
    {
      "Name": "CDK12 rearrangement exon 4",
      "Clinical": [],
      "No Clinical": []
    },
    { "Name": "RICTOR amplification", "Clinical": [], "No Clinical": [] },
    { "Name": "CDKN2A/B p16INK4a G89V", "Clinical": [], "No Clinical": [] },
    { "Name": "FAM123B G605D", "Clinical": [], "No Clinical": [] },
    { "Name": "TP53 loss exons 10-11", "Clinical": [], "No Clinical": [] }
  ],
  "Biomakers findings": [
    {
      "Name": "Microsatellite status - MS-Stable",
      "Clinical": [],
      "No Clinical": []
    },
    {
      "Name": "Tumor Mutational Burden - 3 Muts/Mb",
      "Clinical": [],
      "No Clinical": []
    }
  ]
}